AboutPortfolioInvestment FocusLeadershipInsightsContact Partner With Us
Leadership

The Minds Behind
MedLinks Capital

Our team combines decades of healthcare investing, clinical science, and operational leadership — united by a shared belief that extraordinary outcomes begin with extraordinary people.

Core Team

Our People

Dr. Harry R. Jacobson
Dr. Harry R. Jacobson
Chairman & Strategic Advisor
Physician, entrepreneur, and investor with five decades of healthcare leadership. As CEO of Vanderbilt University Medical Center (1997–2009), grew revenue from $750M to $2.25B and achieved a top-10 NIH funding ranking. Co-founder of Renal Care Group (NYSE, acquired by Fresenius), Contact Software (acquired by Symantec), and CeloNova Biosciences — with a product line sold to Boston Scientific for up to $270M. Former board member of Merck and KCI; elected to the National Academy of Sciences and Tennessee Healthcare Hall of Fame.
Andrew Jacobson
Andrew Jacobson
Managing Partner
Healthcare investor, co-founder, and capital markets strategist with $32M+ raised across real estate, software, healthcare services, and biotechnology. Andrew has co-founded or led capital raises for MedLogic ($3.25M raised, $65M in claims receivables), CNS Biosciences (Emeramide/Irminix® Phase 2, targeting Progressive Supranuclear Palsy and Parkinson's), Gradalis (FDA RMAT-designated personalised cancer immunotherapy, Phase 3-ready), and Virtuoso Surgical (FDA Breakthrough Device designation). His expertise spans entity formation, exclusive licence negotiation, and cross-border capital facilitation across a high-conviction life sciences portfolio.
Gurdev Chimni
Gurdev Chimni
Managing Partner
Strategic relationship builder and healthcare-focused investor with a deep North American network spanning family offices, healthcare executives, and institutional stakeholders. At MedLinks Capital, Gurdev leads deal origination, capital formation, and strategic partnership facilitation across healthcare services, biotechnology, and medical innovation — with investments including Gradalis (oncology immunotherapy), Virtuoso Surgical (FDA Breakthrough Device designation), and Lobe Sciences. A former professional golfer who competed internationally, he brings a relationship-first philosophy shaped by years in high-performance environments.
Advisory Board

World-Class Advisors

Our advisory board brings together leading clinicians, regulatory experts, and industry executives who provide strategic guidance and open doors across the global healthcare ecosystem.

Prof. Sarah Chen
Clinical Genomics
Chair of Clinical Genomics at Johns Hopkins. Global authority on gene therapy trial design and regulatory strategy for rare diseases.
Dr. Michael Torres
Digital Health Policy
Former FDA Deputy Commissioner. Leads our regulatory intelligence capabilities across digital health, AI diagnostics, and SaMD frameworks.
Priya Krishnamurthy
APAC Market Access
Ex-CEO of Asia Pacific Health Systems. Guides our APAC investment strategy and cross-border commercialisation partnerships.